Truist raised the firm’s price target on Aveanna to $1.70 from $1.40 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The firm remains bullish on the group’s long-term tailwinds, but utilization creates near-term uncertainty with opportunity across sectors. The recent Medicare utilization comments have caused MCO skittishness, but Truist also “sees offsets” and believes that valuations in the sector remain “noticeably discounted”, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVAH:
- Aveanna reaffirms 2023 revenue view of at least $1.84B, consensus $1.87B
- Aveanna appoints Debbie Stewart as Principal Accounting Officer
- Aveanna CFO David Afshar resigns, Matt Buckhalter named interim
- Aveanna Announces Resignation of Chief Financial Officer; Announces Corresponding Appointments; Reaffirms FY 2023 Guidance